InMed Pharmaceuticals宣布500万美元私募

2025-06-25 20:54

InMed Pharmaceuticals (NASDAQ:INM) has entered into definitive agreements for the issuance and sale of 1.95M of its common shares and short-term preferred investment options to purchase up to an aggregate of 1.95M common shares, at a purchase price of $2.561 per share.
The aggregate gross proceeds to the company from the offering are expected to be about $5M, before deducting placement agent fees and other offering expenses.
The offering is expected to close on or about June 25, 2025.
The company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, support commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and for general working capital purposes.
The company also has agreed to amend certain existing preferred investment options to purchase up to an aggregate of 199,115 common shares that were previously issued in October 2023 and have an exercise price of $16.60 per share, for $0.125 per amended preferred investment option, effective upon the closing of the offering, such that the amended preferred investment options will have a reduced exercise price of $2.436 per share.
INM -15.24% premarket to $3.28.
Source: Press Release

More on InMed Pharmaceuticals